Download PDF
CC BY 4.0 · Surg J (N Y) 2016; 02(01): e29-e43
DOI: 10.1055/s-0036-1579657
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Why Do Patients Bleed?

Jennifer Curnow
1   Department of Clinical and Laboratory Hematology, Institute of Clinical Pathology and Medical Research and Westmead Hospital, Sydney Centres for Thrombosis and Hemostasis, Westmead, Australia
,
Leonardo Pasalic
1   Department of Clinical and Laboratory Hematology, Institute of Clinical Pathology and Medical Research and Westmead Hospital, Sydney Centres for Thrombosis and Hemostasis, Westmead, Australia
2   Pathology West, NSW Health Pathology, Westmead, Australia
,
Emmanuel J. Favaloro
1   Department of Clinical and Laboratory Hematology, Institute of Clinical Pathology and Medical Research and Westmead Hospital, Sydney Centres for Thrombosis and Hemostasis, Westmead, Australia
2   Pathology West, NSW Health Pathology, Westmead, Australia
› Author Affiliations
Further Information

Publication History

02 November 2015

01 February 2016

Publication Date:
24 February 2016 (online)

   Permissions and Reprints

Abstract

Patients undergoing surgical procedures can bleed for a variety of reasons. Assuming that the surgical procedure has progressed well and that the surgeon can exclude surgical reasons for the unexpected bleeding, then the bleeding may be due to structural (anatomical) anomalies or disorders, recent drug intake, or disorders of hemostasis, which may be acquired or congenital. The current review aims to provide an overview of reasons that patients bleed in the perioperative setting, and it also provides guidance on how to screen for these conditions, through consideration of appropriate patient history and examination prior to surgical intervention, as well as guidance on investigating and managing the cause of unexpected bleeding.

Keywords

surgery - bleeding - hemostasis - platelet function - coagulation
 

  • References

  • 1 Laffan M, Manning R. Investigation of hemostasis. In: Lewis S, Bain B, Bates I. eds. Dacie and Lewis Practical Hematology. London, UK: Churchill Livingstone; 2001: 339-390
    Google Scholar
  • 2 Kazmi RS, Boyce S, Lwaleed BA. Homeostasis of hemostasis: the role of endothelium. Semin Thromb Hemost 2015; 41 (06) 549-555
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Fay WP, Garg N, Sunkar M. Vascular functions of the plasminogen activation system. Arterioscler Thromb Vasc Biol 2007; 27 (06) 1231-1237
    CrossrefPubMedGoogle Scholar
  • 4 van Hinsbergh VW. Endothelium—role in regulation of coagulation and inflammation. Semin Immunopathol 2012; 34 (01) 93-106
    CrossrefPubMedGoogle Scholar
  • 5 Vanhoutte PM, Tang EH. Endothelium-dependent contractions: when a good guy turns bad!. J Physiol 2008; 586 (Pt 22): 5295-5304
    CrossrefPubMedGoogle Scholar
  • 6 Félétou M, Huang Y, Vanhoutte PM. Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 2011; 164 (03) 894-912
    CrossrefPubMedGoogle Scholar
  • 7 Berndt MC, Ward CM, De Luca M. , et al. The molecular mechanism of platelet adhesion. Aust N Z J Med 1995; 25 (06) 822-830
    CrossrefPubMedGoogle Scholar
  • 8 Hoffman M, Monroe III DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85 (06) 958-965
    PubMedGoogle Scholar
  • 9 Roberts HR, Hoffman M, Monroe DM. A cell-based model of thrombin generation. Semin Thromb Hemost 2006; 32 (Suppl. 01) 32-38
    PubMedGoogle Scholar
  • 10 Davie EW, Ratnoff OD. Waterfall sequence for intrinsic blood clotting. Science 1964; 145 (3638): 1310-1312
    CrossrefPubMedGoogle Scholar
  • 11 MacFarlane RG. An enzyme cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature 1964; 202: 498-499
    CrossrefPubMedGoogle Scholar
  • 12 Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002; 22 (09) 1381-1389
    CrossrefPubMedGoogle Scholar
  • 13 Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. Blood 1995; 86 (05) 1794-1801
    PubMedGoogle Scholar
  • 14 Bogdanov VY, Versteeg HH. “Soluble tissue factor” in the 21st century: definitions, biochemistry, and pathophysiological role in thrombus formation. Semin Thromb Hemost 2015; 41 (07) 700-707
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Cimmino G, Ciccarelli G, Golino P. Role of tissue factor in the coagulation network. Semin Thromb Hemost 2015; 41 (07) 708-717
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Maugeri N, Manfredi AA. Tissue factor expressed by neutrophils: another piece in the vascular inflammation puzzle. Semin Thromb Hemost 2015; 41 (07) 728-736
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Heemskerk JWM, Mattheij NJA, Cosemans JMEM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost 2013; 11 (01) 2-16
    PubMedGoogle Scholar
  • 18 Scott EM, Ariëns RA, Grant PJ. Genetic and environmental determinants of fibrin structure and function: relevance to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24 (09) 1558-1566
    CrossrefPubMedGoogle Scholar
  • 19 Schroeder V, Kohler HP. Factor XIII deficiency: an update. Semin Thromb Hemost 2013; 39 (06) 632-641
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Kwaan HC, Mazar AP. Biologic role of the plasminogen-plasmin system: thrombolysis, bleeding, and beyond. Semin Thromb Hemost 2013; 39 (04) 327-328
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Rijken DC, Lijnen HR. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 2009; 7 (01) 4-13
    CrossrefPubMedGoogle Scholar
  • 22 Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112 (01) 19-27
    CrossrefPubMedGoogle Scholar
  • 23 Lane DA, Philippou H, Huntington JA. Directing thrombin. Blood 2005; 106 (08) 2605-2612
    CrossrefPubMedGoogle Scholar
  • 24 Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost 2003; 1 (07) 1504-1514
    CrossrefPubMedGoogle Scholar
  • 25 Chen D, Dorling A. Critical roles for thrombin in acute and chronic inflammation. J Thromb Haemost 2009; 7 (Suppl. 01) 122-126
    CrossrefPubMedGoogle Scholar
  • 26 Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime?. Trends Immunol 2007; 28 (04) 184-192
    CrossrefPubMedGoogle Scholar
  • 27 Jaffe EA, Hoyer LW, Nachman RL. Synthesis of von Willebrand factor by cultured human endothelial cells. Proc Natl Acad Sci U S A 1974; 71 (05) 1906-1909
    CrossrefPubMedGoogle Scholar
  • 28 Sporn LA, Chavin SI, Marder VJ, Wagner DD. Biosynthesis of von Willebrand protein by human megakaryocytes. J Clin Invest 1985; 76 (03) 1102-1106
    CrossrefPubMedGoogle Scholar
  • 29 Sadler JE, Budde U, Eikenboom JC. , et al; Working Party on von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4 (10) 2103-2114
    CrossrefPubMedGoogle Scholar
  • 30 Yee A, Kretz CA. Von Willebrand factor: form for function. Semin Thromb Hemost 2014; 40 (01) 17-27
    PubMedGoogle Scholar
  • 31 Peyvandi F, Garagiola I, Baronciani L. Role of von Willebrand factor in the haemostasis. Blood Transfus 2011; 9 (Suppl. 02) s3-s8
    PubMedGoogle Scholar
  • 32 Koh SC, Pua HL, Tay DH, Ratnam SS. The effects of gynaecological surgery on coagulation activation, fibrinolysis and fibrinolytic inhibitor in patients with and without ketorolac infusion. Thromb Res 1995; 79 (5–6): 501-514
    CrossrefPubMedGoogle Scholar
  • 33 Sørensen JV. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma. Blood Coagul Fibrinolysis 1994; 5 (01) 43-49
    CrossrefPubMedGoogle Scholar
  • 34 Borgstrom S, Gelin LE, Zederfeldt B. The formation of vein thrombi following tissue injury: an experimental study in rabbits. Acta Chir Scand Suppl 1959; 247 (Suppl 247): 1-36
    PubMedGoogle Scholar
  • 35 Kluft C, Verheijen JH, Jie AF. , et al. The postoperative fibrinolytic shutdown: a rapidly reverting acute phase pattern for the fast-acting inhibitor of tissue-type plasminogen activator after trauma. Scand J Clin Lab Invest 1985; 45 (07) 605-610
    CrossrefPubMedGoogle Scholar
  • 36 Kambayashi J, Sakon M, Yokota M, Shiba E, Kawasaki T, Mori T. Activation of coagulation and fibrinolysis during surgery, analyzed by molecular markers. Thromb Res 1990; 60 (02) 157-167
    CrossrefPubMedGoogle Scholar
  • 37 Myers DD, Hawley AE, Farris DM. , et al. P-selectin and leukocyte microparticles are associated with venous thrombogenesis. J Vasc Surg 2003; 38 (05) 1075-1089
    CrossrefPubMedGoogle Scholar
  • 38 Hamer JD, Malone PC, Silver IA. The PO2 in venous valve pockets: its possible bearing on thrombogenesis. Br J Surg 1981; 68 (03) 166-170
    CrossrefPubMedGoogle Scholar
  • 39 Comerota AJ, Stewart GJ, Alburger PD, Smalley K, White JV. Operative venodilation: a previously unsuspected factor in the cause of postoperative deep vein thrombosis. Surgery 1989; 106 (02) 301-308 , discussion 308–309
    PubMedGoogle Scholar
  • 40 Martini WZ. Coagulopathy by hypothermia and acidosis: mechanisms of thrombin generation and fibrinogen availability. J Trauma 2009; 67 (01) 202-208 , discussion 208–209
    CrossrefPubMedGoogle Scholar
  • 41 Avorn J, Patel M, Levin R, Winkelmayer WC. Hetastarch and bleeding complications after coronary artery surgery. Chest 2003; 124 (04) 1437-1442
    CrossrefPubMedGoogle Scholar
  • 42 Aglietti P, Baldini A, Vena LM, Abbate R, Fedi S, Falciani M. Effect of tourniquet use on activation of coagulation in total knee replacement. Clin Orthop Relat Res 2000; (371) 169-177
    PubMedGoogle Scholar
  • 43 Levy JH, Sniecinski RM. Prohemostatic treatment in cardiac surgery. Semin Thromb Hemost 2012; 38 (03) 237-243
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Ranucci M. Hemostatic and thrombotic issues in cardiac surgery. Semin Thromb Hemost 2015; 41 (01) 84-90
    Article in Thieme ConnectPubMedGoogle Scholar
  • 45 Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318 (18) 1162-1173
    CrossrefPubMedGoogle Scholar
  • 46 Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999; 104 (02) 208-219
    CrossrefPubMedGoogle Scholar
  • 47 Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990; 76 (09) 1680-1697
    PubMedGoogle Scholar
  • 48 Kitchens CS. Occult hemophilia. Johns Hopkins Med J 1980; 146 (06) 255-259
    PubMedGoogle Scholar
  • 49 Zumberg MS, Waples JM, Kao KJ, Lottenberg R. Management of a patient with a mechanical aortic valve and antibodies to both thrombin and factor V after repeat exposure to fibrin sealant. Am J Hematol 2000; 64 (01) 59-63
    CrossrefPubMedGoogle Scholar
  • 50 Favaloro EJ, Posen J, Ramakrishna R. , et al. Factor V inhibitors: rare or not so uncommon? A multi-laboratory investigation. Blood Coagul Fibrinolysis 2004; 15 (08) 637-647
    CrossrefPubMedGoogle Scholar
  • 51 Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 2014; 28 (03) 107-113
    CrossrefPubMedGoogle Scholar
  • 52 Stellingwerff M, Brandsma A, Lisman T, Porte RJ. Prohemostatic interventions in liver surgery. Semin Thromb Hemost 2012; 38 (03) 244-249
    Article in Thieme ConnectPubMedGoogle Scholar
  • 53 Tripodi A. Liver disease and hemostatic (dys)function. Semin Thromb Hemost 2015; 41 (05) 462-467
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Lisman T, Kwaan HC. Hemostatic dysfunction in liver diseases. Semin Thromb Hemost 2015; 41 (05) 445-446
    Article in Thieme ConnectPubMedGoogle Scholar
  • 55 Hoffman M. Coagulation in liver disease. Semin Thromb Hemost 2015; 41 (05) 447-454
    Article in Thieme ConnectPubMedGoogle Scholar
  • 56 Narr BJ, Warner ME, Schroeder DR, Warner MA. Outcomes of patients with no laboratory assessment before anesthesia and a surgical procedure. Mayo Clin Proc 1997; 72 (06) 505-509
    CrossrefPubMedGoogle Scholar
  • 57 Toker A, Shvarts S, Perry ZH, Doron Y, Reuveni H. Clinical guidelines, defensive medicine, and the physician between the two. Am J Otolaryngol 2004; 25 (04) 245-250
    CrossrefPubMedGoogle Scholar
  • 58 Chee YL, Crawford JC, Watson HG, Greaves M. ; British Committee for Standards in Haematology. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. Br J Haematol 2008; 140 (05) 496-504
    CrossrefPubMedGoogle Scholar
  • 59 Bowie EJW, Owen Jr CA. The significance of abnormal preoperative hemostatic tests. Prog Hemost Thromb 1980; 5: 179-209
    PubMedGoogle Scholar
  • 60 Burk CD, Miller L, Handler SD, Cohen AR. Preoperative history and coagulation screening in children undergoing tonsillectomy. Pediatrics 1992; 89 (4 Pt 2): 691-695
    PubMedGoogle Scholar
  • 61 Haberman II RS, Shattuck TG, Dion NM. Is outpatient suction cautery tonsillectomy safe in a community hospital setting?. Laryngoscope 1990; 100 (05) 511-515
    PubMedGoogle Scholar
  • 62 Suchman AL, Mushlin AI. How well does the activated partial thromboplastin time predict postoperative hemorrhage?. JAMA 1986; 256 (06) 750-753
    CrossrefPubMedGoogle Scholar
  • 63 Bachmann F. Diagnostic approach to mild bleeding disorders. Semin Hematol 1980; 17 (04) 292-305
    PubMedGoogle Scholar
  • 64 Kitchens CS. Prolonged activated partial thromboplastin time of unknown etiology: a prospective study of 100 consecutive cases referred for consultation. Am J Hematol 1988; 27 (01) 38-45
    CrossrefPubMedGoogle Scholar
  • 65 Rapaport SI. Preoperative hemostatic evaluation: which tests, if any?. Blood 1983; 61 (02) 229-231
    PubMedGoogle Scholar
  • 66 Lippi G, Favaloro EJ, Franchini M. Dangers in the practice of defensive medicine in hemostasis testing for investigation of bleeding or thrombosis: part I—routine coagulation testing. Semin Thromb Hemost 2014; 40 (07) 812-824
    Article in Thieme ConnectPubMedGoogle Scholar
  • 67 Scharf RE. Drugs that affect platelet function. Semin Thromb Hemost 2012; 38 (08) 865-883
    Article in Thieme ConnectPubMedGoogle Scholar
  • 68 McEwen BJ. The influence of diet and nutrients on platelet function. Semin Thromb Hemost 2014; 40 (02) 214-226
    Article in Thieme ConnectPubMedGoogle Scholar
  • 69 McEwen BJ. The influence of herbal medicine on platelet function and coagulation: a narrative review. Semin Thromb Hemost 2015; 41 (03) 300-314
    Article in Thieme ConnectPubMedGoogle Scholar
  • 70 Lippi G, Pasalic L, Favaloro EJ. Detection of mild inherited disorders of blood coagulation: current options and personal recommendations. Expert Rev Hematol 2015; 8 (04) 527-542
    CrossrefPubMedGoogle Scholar
  • 71 Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34 (08) 709-733
    Article in Thieme ConnectPubMedGoogle Scholar
  • 72 Nichols WL, Hultin MB, James AH. , et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008; 14 (02) 171-232
    CrossrefPubMedGoogle Scholar
  • 73 Favaloro EJ. Von Willebrand disease: local diagnosis and management of a globally distributed bleeding disorder. Semin Thromb Hemost 2011; 37 (05) 440-455
    Article in Thieme ConnectPubMedGoogle Scholar
  • 74 Favaloro EJ, Bodó I, Israels SJ, Brown SA. von Willebrand disease and platelet disorders. Haemophilia 2014; 20 (Suppl. 04) 59-64
    CrossrefPubMedGoogle Scholar
  • 75 Kim JH, Baek CH, Min JY, Kim JS, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol 2015; 94 (09) 1457-1461
    CrossrefPubMedGoogle Scholar
  • 76 Lee HK, Kim YJ, Jeong JU, Park JS, Chi HS, Kim SB. Desmopressin improves platelet dysfunction measured by in vitro closure time in uremic patients. Nephron Clin Pract 2010; 114 (04) c248-c252
    CrossrefPubMedGoogle Scholar
  • 77 Rodeghiero F. Von Willebrand disease: pathogenesis and management. Thromb Res 2013; 131 (Suppl. 01) S47-S50
    CrossrefPubMedGoogle Scholar
  • 78 Franchini M, Crestani S, Frattini F, Sissa C, Bonfanti C. Hemostatic agents for bleeding: recombinant-activated factor VII and beyond. Semin Thromb Hemost 2015; 41 (03) 342-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Tjønnfjord GE, Brinch L, Gedde-Dahl III T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004; 10 (02) 174-178
    CrossrefPubMedGoogle Scholar
  • 80 Lin Y, Moltzan CJ, Anderson DR. ; National Advisory Committee on Blood and Blood Products. The evidence for the use of recombinant factor VIIa in massive bleeding: revision of the transfusion policy framework. Transfus Med 2012; 22 (06) 383-394
    CrossrefPubMedGoogle Scholar
  • 81 Othman M. Rare bleeding disorders: genetic, laboratory, clinical, and molecular aspects. Preface. Semin Thromb Hemost 2013; 39 (06) 575-578
    Article in Thieme ConnectPubMedGoogle Scholar
  • 82 Peyvandi F, Menegatti M, Palla R. Rare bleeding disorders: worldwide efforts for classification, diagnosis, and management. Semin Thromb Hemost 2013; 39 (06) 579-584
    Article in Thieme ConnectPubMedGoogle Scholar
  • 83 Shander A, Javidroozi M. The approach to patients with bleeding disorders who do not accept blood-derived products. Semin Thromb Hemost 2013; 39 (02) 182-190
    Article in Thieme ConnectPubMedGoogle Scholar
  • 84 Darvish-Kazem S, Douketis JD. Perioperative management of patients having noncardiac surgery who are receiving anticoagulant or antiplatelet therapy: an evidence-based but practical approach. Semin Thromb Hemost 2012; 38 (07) 652-660
    Article in Thieme ConnectPubMedGoogle Scholar
  • 85 Franchini M, Bonfanti C, Mannucci PM. Management of bleeding associated with new oral anticoagulants. Semin Thromb Hemost 2015; 41 (07) 788-801
    Article in Thieme ConnectPubMedGoogle Scholar
  • 86 Cervellin G, Benatti M, Bonfanti L, Lippi G. Quality and safety issues of direct oral anticoagulants in the emergency department. Semin Thromb Hemost 2015; 41 (03) 348-354
    Article in Thieme ConnectPubMedGoogle Scholar
  • 87 Goy J, Crowther M. Approaches to diagnosing and managing anticoagulant-related bleeding. Semin Thromb Hemost 2012; 38 (07) 702-710
    Article in Thieme ConnectPubMedGoogle Scholar
  • 88 Pollack Jr CV, Reilly PA, Eikelboom J. , et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373 (06) 511-520
    CrossrefPubMedGoogle Scholar
  • 89 Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015; 41 (02) 208-227
    Article in Thieme ConnectPubMedGoogle Scholar
  • 90 Franchini M, Favaloro EJ, Lippi G. Newer hemostatic agents. Semin Thromb Hemost 2015; 41 (07) 802-808
    Article in Thieme ConnectPubMedGoogle Scholar
  • 91 Palla R, Peyvandi F, Shapiro AD. Rare bleeding disorders: diagnosis and treatment. Blood 2015; 125 (13) 2052-2061
    CrossrefPubMedGoogle Scholar
  • 92 Mumford AD, Ackroyd S, Alikhan R. , et al; BCSH Committee. Guideline for the diagnosis and management of the rare coagulation disorders: a United Kingdom Haemophilia Centre Doctors' Organization guideline on behalf of the British Committee for Standards in Haematology. Br J Haematol 2014; 167 (03) 304-326
    CrossrefPubMedGoogle Scholar
  • 93 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al. WFH Guidelines for the Management of Hemophilia. 2nd ed. Available at: http://www.wfh.org/en/resources/wfh-treatment-guidelines? . Accessed November 2, 2015
    PubMedGoogle Scholar
  • 94 Rydz N, James PD. Approach to the diagnosis and management of common bleeding disorders. Semin Thromb Hemost 2012; 38 (07) 711-719
    Article in Thieme ConnectPubMedGoogle Scholar
  • 95 Curnow J, Pasalic L, Favaloro EJ. Treatment of von Willebrand disease. Semin Thromb Hemost 2016; 42 (02) 133-146
    Article in Thieme ConnectPubMedGoogle Scholar